Evidence map›Paper›PMID 40719840›Full record

ArticleMedical oncology (Northwood, London, England)2025

Investigation of the antitumor activity of lapatinib and NNC 55-0396 dihydrochloride combination in gastric adenocarcinoma.

Muhammed Gömeç, Fatih Yulak, Mustafa Ergül

Abstract read
PubMed Publisher
In one paragraph

Article in Medical oncology (Northwood, London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Muhammed GömeçDepartment of General Surgery Sivas Medicana Hospital, Sivas, Turkey. drmuhammedgomec@yahoo.com.ORCID http://orcid.org/0000-0002-9127-3201
Fatih YulakFaculty of Medicine, Department of Physiology, Sivas Cumhuriyet University, Sivas, Turkey.ORCID http://orcid.org/0000-0003-3708-6752
Mustafa ErgülFaculty of Pharmacy, Department of Biochemistry, Sivas Cumhuriyet University, Sivas, Turkey.ORCID http://orcid.org/0000-0003-4303-2996

Funding

Sivas Cumhuriyet Üniversitesi,Türkiye T-2021-915
6 · The paper itself

Abstract

Targeted drugs such as Lapatinib and Everolimus have limited efficacy in the treatment of gastric cancer due to heterogeneous tumor structure. Combination therapies may offer a promising alternative to overcome this limitation. In this study, the potential synergistic effects of the combination of T-type calcium channel blocker NNC 55-0396 dihydrochloride (NNC) with Lapatinib and Everolimus were investigated in gastric cancer cell lines. In the first stage of the experiment, all three drugs were applied to AGS and SNU-1 cell lines at different doses, and IC

Indexed as

AdenocarcinomaAntineoplastic Combined Chemotherapy ProtocolsQuinazolinesStomach NeoplasmsApoptosisCell Line, TumorCell ProliferationDrug SynergismEverolimusHumansLapatinibEverolimusLapatinibQuinazolinesAnticancerCalcium channel blockerGastric cancerLapatinibNNC 55-0396 dihydrochloride

Identifiers

PMID40719840

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.